Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 21

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 21
---
 “ The Merger Agreement—Conditions to the Merger” below.

Termination (see page 35)

The Merger Agreement contains certain customary termination rights, including the right of either MIRA or SKNY to terminate the Merger Agreement if either company’s stockholders fail to adopt and approve the Merger Proposal, if the Closing has not occurred by December 31, 2025, if a governmental entity has issued a final ruling prohibiting the Closing, or by one party upon an uncured breach of the Merger Agreement.

For a more complete description of the termination provisions, please see the section titled “ The Merger Agreement—Termination.”

Appraisal Rights and Dissenters’ Rights (see page 36)

Pursuant to Section 607.1302 of the Florida Business Corporation Act, the shareholders of MIRA will not be entitled to appraisal rights as a result of the Merger.

| 8 |

Executive Officers of the Combined Company Following the Merger (see page 31) Immediately following the Merger, the executive management team of the MIRA is expected to remain the same as prior to the Merger and be comprised of the following individuals with such additional officers as may be added by the combined company:

| Name                   |     | Position          
 with MIRA         |
| Erez                   
 Aminov                 |     | Chief             
 Executive Officer |
| Alan                   
 Weichselbaum, CPA, MBA |     | Chief             
 Financial Officer |

Directors of the Combined Company Following the Merger (see page 32) Following the Merger, MIRA is expected to maintain four of the directors that were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov, Edward MacPherson and Dr. Matthew Del Giudice, with Dr. Denil Nanji Shekhat being replaced by Kelly Stackpole, the current CEO of SKNY, at the closing of the Merger, each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. For more information about the executive officers and directors of MIRA following the Merger, please see the section titled “ Management Following the Merger.” Interests of the MIRA Directors, Executive Officers and Affiliate Shareholders in the Merger (see page 31) In considering the recommendation of the MIRA Board with respect to the issuance of MIRA Common Stock pursuant to the Merger Agreement and the other matters to be acted upon by MIRA’s stockholders at